<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kala Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc</link>
<description>Latest news and press releases for Kala Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kala-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358da078dffbe2df100dfd.webp</url>
<title>Kala Pharmaceuticals Inc</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc</link>
</image>
<item>
<title>Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-celebrates-trump-executive-order-as-game-changer-for-psychedelic-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-celebrates-trump-executive-order-as-game-changer-for-psychedelic-medicine</guid>
<pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
<description>Historic U.S. Executive Order Fast-Tracks Psychedelic Research Access; Landmark Policy Shift Strengthens the Outlook for KALA’s Client Red Light Holland and Positions Researgency.ai as the Dedicated AI Infrastructure Partner for the Global Psychedelic and Biotech Drug Development IndustryARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 20</description>
</item>
<item>
<title>Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-engages-dr-saeid-babaei-as-senior-scientific-advisor-to-evaluate-clinical-assets-and-precision-development-opportunities-2</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-engages-dr-saeid-babaei-as-senior-scientific-advisor-to-evaluate-clinical-assets-and-precision-development-opportunities-2</guid>
<pubDate>Wed, 01 Apr 2026 10:45:00 GMT</pubDate>
<description>Engagement will assess KALA’s clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platformTORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation, today announced the engagement of Dr. Saeid Babaei, PhD, MBA, as Senior Scientific Advisor. Dr. Babaei’s engagement will focus on advising on the evaluation</description>
</item>
<item>
<title>KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-delivers-industry-leading-ai-infrastructure-bionic-intelligence-research-agent-now-live</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-delivers-industry-leading-ai-infrastructure-bionic-intelligence-research-agent-now-live</guid>
<pubDate>Mon, 30 Mar 2026 12:45:00 GMT</pubDate>
<description>Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical OrganizationsARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-built agentic AI solution delivered through its Researgency.ai platform (un</description>
</item>
<item>
<title>Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filaments-patented-pex010-botanical-psilocybin-drug-candidate-1</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filaments-patented-pex010-botanical-psilocybin-drug-candidate-1</guid>
<pubDate>Wed, 18 Mar 2026 13:00:00 GMT</pubDate>
<description>AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intell</description>
</item>
<item>
<title>Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filament-healths-patented-pex010-botanical-psilocybin-drug-candidate-1</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/red-light-holland-engages-kala-bios-researgencyai-platform-to-support-clinical-development-of-filament-healths-patented-pex010-botanical-psilocybin-drug-candidate-1</guid>
<pubDate>Wed, 18 Mar 2026 12:15:00 GMT</pubDate>
<description>AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industryToronto, Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's Researgency.ai agentic...</description>
</item>
<item>
<title>Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-launches-a-revolution-for-biotech-first-ai-agent-deploying-in-14-days-as-dollar180-billion-agentic-ai-healthcare-revolution-accelerates</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-launches-a-revolution-for-biotech-first-ai-agent-deploying-in-14-days-as-dollar180-billion-agentic-ai-healthcare-revolution-accelerates</guid>
<pubDate>Wed, 11 Mar 2026 10:30:00 GMT</pubDate>
<description>Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two WeeksARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market. Kal</description>
</item>
<item>
<title>KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-strategic-initiative-to-deploy-and-continue-to-develop-an-on-premises-ai-infrastructure-platform-for-the-biotech-industry-enters-into-platform-development-and-exclusive-license-agreement-for-proprietary-ai-research-platform-researgency</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-strategic-initiative-to-deploy-and-continue-to-develop-an-on-premises-ai-infrastructure-platform-for-the-biotech-industry-enters-into-platform-development-and-exclusive-license-agreement-for-proprietary-ai-research-platform-researgency</guid>
<pubDate>Wed, 04 Mar 2026 11:30:00 GMT</pubDate>
<description>Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s controlPlatform-as-a-service model designed to generate recurring revenue by licensing AI capabilities to biotech and pharmaceutical companies of all sizes — addressing a market where the top 20 pharma companies invested approximately $167 billion in R&D in 2024 bu</description>
</item>
<item>
<title>KALA BIO Settles Approximately $10.6 million of Debt</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-settles-approximately-10-211000091</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-settles-approximately-10-211000091</guid>
<pubDate>Mon, 05 Jan 2026 21:10:00 GMT</pubDate>
<description>ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations. As previously disclosed in the Company’s Current Report on Form 8-K filed on November 25, 2025, KALA and its subsidiary Combangio, Inc., entered into a Loan Settlement</description>
</item>
<item>
<title>KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-closing-10-193600187</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-closing-10-193600187</guid>
<pubDate>Fri, 05 Dec 2025 19:36:00 GMT</pubDate>
<description>ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof). H.C. Wainwright & Co. acted as the exclusive placement agent for the offe</description>
</item>
<item>
<title>KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-10-million-154500369</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-10-million-154500369</guid>
<pubDate>Thu, 04 Dec 2025 15:45:00 GMT</pubDate>
<description>ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about</description>
</item>
<item>
<title>KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-enters-6-million-120000668</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-enters-6-million-120000668</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transactionARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, announces it has entered into a $6 million securi</description>
</item>
<item>
<title>KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-topline-results-120000593</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-topline-results-120000593</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related serious adverse events observed -- -- KALA to cease clinical development of KPI-012, preserve cash and explore strategic options -- ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development</description>
</item>
<item>
<title>KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-present-h-c-120000417</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-present-h-c-120000417</guid>
<pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
<description>ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY on Wednesday, September 10, 2025 at 2:00 p.m. ET. Management will be available for one-on-one meeting</description>
</item>
<item>
<title>KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-appoints-todd-bazemore-120000881</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-appoints-todd-bazemore-120000881</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companiesARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KA</description>
</item>
<item>
<title>KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-reports-second-quarter-120000228</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-reports-second-quarter-120000228</guid>
<pubDate>Fri, 08 Aug 2025 12:00:00 GMT</pubDate>
<description>-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe d</description>
</item>
<item>
<title>KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-present-h-c-120000489</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-present-h-c-120000489</guid>
<pubDate>Wed, 06 Aug 2025 12:00:00 GMT</pubDate>
<description>ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on Wednesday, August 13, 2025. A pre-recorded presentation will be made available beginning on Wednesday,</description>
</item>
<item>
<title>KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-completion-enrollment-120000363</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-announces-completion-enrollment-120000363</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the completion</description>
</item>
<item>
<title>KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-host-virtual-key-120000034</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-host-virtual-key-120000034</guid>
<pubDate>Mon, 07 Jul 2025 12:00:00 GMT</pubDate>
<description>ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss the potential of KPI-012 for the treatment of persistent corneal epithelial defect (PCED). The event will take place on Wednesday, July 16, 2025, a</description>
</item>
<item>
<title>KALA BIO to Present at Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-present-jefferies-global-120000008</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-present-jefferies-global-120000008</guid>
<pubDate>Thu, 29 May 2025 12:00:00 GMT</pubDate>
<description>ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5,</description>
</item>
<item>
<title>KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-reports-first-quarter-120000479</link>
<guid isPermaLink="true">https://6ix.com/company/kala-pharmaceuticals-inc/news/kala-bio-reports-first-quarter-120000479</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as of March 31, 2025, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the ey</description>
</item>
</channel>
</rss>